Medicare Reform Triggers Significant Drop in Prescription Rationing Among 70,000 Heart Disease Patients Nationwide

ACC.26 study shows 70,000 seniors stopped skipping heart meds in 2024 after Inflation Reduction Act caps lowered out-of-pocket prescription costs.

By: AXL Media

Published: Mar 24, 2026, 8:58 AM EDT

Source: Information for this report was sourced from American College of Cardiology

Legislative Impact on Cardiovascular Medication Adherence

The implementation of the 2022 Inflation Reduction Act has led to a measurable decrease in cost-related medication non-adherence among Medicare beneficiaries with cardiovascular risks. According to research led by Dr. Lucas Marinacci of Beth Israel Deaconess Medical Center, provisions that went into effect on January 1, 2024, provided immediate relief for seniors who previously rationed their prescriptions. The study suggests that by lowering the financial barrier to entry for life-saving drugs, the federal policy has effectively encouraged patients to maintain their prescribed treatment regimens, potentially averting serious cardiac events.

Strategic Expansion of Federal Subsidy Eligibility

One of the primary drivers of this improved adherence was the expansion of the "extra help" subsidy program. Prior to 2024, full subsidies were restricted to individuals with incomes up to 135% of the federal poverty level, but the new provisions extended this support to those at 150% of the poverty level. This shift created a newly eligible bracket of seniors who saw a 5.5 percentage point decrease in reported medication skipping or delaying. By widening the safety net, the policy addressed a critical gap for low-income patients who were previously considered too wealthy for aid but remained too poor to afford rising drug costs.

Structural Changes to Catastrophic Coverage Requirements

Beyond income-based subsidies, the 2024 reforms eliminated the 5% coinsurance requirement for catastrophic coverage within Medicare Part D. This structural change essentially capped the total annual out-of-pocket expenditure for beneficiaries, providing a predictable financial ceiling for those requiring expensive drug classes like SGLT2 inhibitors or novel anticoagulants. When compared to a control group of privately insured adults aged 60-64, Medicare beneficiaries aged 65 and older showed a 2.1 percentage point drop in cost-related non-adherence. This trend remained consistent even after researchers adjusted for variables such as educational attainment, race, and employment status.